Form 4: Seres Therapeutics CEO Eric Shaff Reports Stock Transactions
SEC Form 4 Filing
Seres Therapeutics CEO Eric Shaff reports the acquisition and disposal of common stock and restricted stock units, including sales to cover taxes related to vesting.
Summary
- Eric D. Shaff, CEO and President of Seres Therapeutics, reported transactions involving the company's common stock and restricted stock units.
- On February 15, 2025, Shaff acquired 7,813 and 26,563 shares of common stock through the vesting of restricted stock units.
- On February 18, 2025, Shaff disposed of 12,726 shares of common stock at a weighted average price of $0.8105 per share, with prices ranging from $0.81 to $0.8354.
- These sales were executed under a Rule 10b5-1 trading plan adopted on March 2, 2023, to cover taxes associated with the vesting of restricted stock units.
- Following these transactions, Shaff directly owns 192,039 shares of common stock and 62,500 and 79,687 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by a company executive, with no inherent positive or negative sentiment. The sales are related to tax obligations from vesting RSUs, which is a common practice.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency in insider trading activities.
- The use of Rule 10b5-1 trading plans is a common practice among executives to avoid accusations of insider trading, allowing them to sell shares at predetermined times and prices.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely limited given the relatively small volume of shares sold.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023-03-02 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-02-15 | 25% of the first set of restricted stock units vested and settled. |
| 2025-02-15 | Date of restricted stock unit vesting and settlement. |
| 2025-02-18 | Date of common stock sale. |
| 2025-02-19 | Date of Form 4 signature. |
Keywords
Seres Therapeutics, Eric Shaff, MCRB, Form 4, Stock Transactions, Restricted Stock Units, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.